Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group andevent‐driven phase III clinical trial. The aim of this trial is to confirm thesuperiority of HRS‐7535 over placebo in reducing the risks of renal outcomes andcardiovascular death among participants with chronic kidney disease (CKD) on the basis ofstandard of care
Epistemonikos ID: 187b153c10a12d719185173264129c29127cb810
First added on: Jun 04, 2026